Form 4 for LYEL Lyell Immunopharma, Inc.
Accepted 2026-07-20 14:55:54 ET · period of report 2026-07-17 · accession 0001140361-26-028955 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-07-20 14:55 | 2026-07-17 | LYEL | Innovative Cellular Therapeutics Holdings Ltd | 10% | S - Sale | $13.70 | -10 | 2.86M | -0.0% | -$137 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-17 | S | D | 10 | $13.70 | 2,857,480 | D | — | — | (F1) Reflects 2,857,490 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 10 shares sold. |